LINEAR POLYOL STABILIZED POLYFLUOROACRYLATE COMPOSITIONS

The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract. 3. The process of wherein the polymer comprises structural units corresponding to Formulae 1 claim 1 , 2 and 3.4. The process of wherein the polymer comprises structural units corresponding to Formulae 1 and 2.5. The process of wherein the polymer comprises structural units corresponding to Formulae 1 and 3.6. The process of wherein the cation of the salt is calcium claim 1 , sodium claim 1 , or a combination thereof.7. The process of wherein the cation of the salt comprises calcium.8. The process of wherein the linear sugar alcohol is selected from the group consisting of arabitol claim 1 , erythritol claim 1 , glycerol claim 1 , maltitol claim 1 , mannitol claim 1 , ribitol claim 1 , sorbitol claim 1 , xylitol claim 1 , threitol claim 1 , galactitol claim 1 , isomalt claim 1 , iditol claim 1 , lactitol and combinations thereof.9. The process of wherein the linear sugar alcohol is sorbitol claim 1 , xylitol claim 1 , or a combination thereof.10. The process of wherein the cation of the salt is calcium claim 8 , sodium claim 8 , or a combination thereof.11. The process of wherein the cation of the salt comprises calcium.12. The process of wherein the polymer comprises structural units corresponding to Formulae 1 claim 2 , 2 and 3 claim 2 , the cation of the salt comprises calcium and the linear sugar alcohol comprises sorbitol.14. The process of wherein Ais a protected carboxylic claim 13 , phosphonic claim 13 , or phosphoric.16. The process of wherein the polymer comprises structural units corresponding to Formulae 11 claim 13 , 22 claim 13 , and 33.17. The process of wherein the cation of the salt is calcium claim 13 , sodium claim 13 , or a combination thereof.18. The process of wherein the linear sugar alcohol is selected ...

Linear polyol stabilized polyfluoroacrylate compositions

The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.

CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA

The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract. 1193-. (canceled)196. The pharmaceutical composition of claim 194 , wherein the cation of the crosslinked cation exchange polymer comprises calcium claim 194 , sodium claim 194 , or a combination thereof.197. The pharmaceutical composition of claim 194 , wherein the cation of the crosslinked cation exchange polymer comprises calcium.198. The pharmaceutical composition of claim 197 , wherein m is in the range of from about 87 to about 94 mol % and the ratio of n:p is from about 0.2:1 to about 7:1.199. The pharmaceutical composition of claim 197 , wherein m is in the range of from about 85 to 93 mol % claim 197 , n is in the range of from about 1 to about 10 mol % claim 197 , and p is in the range of from about 1 to about 10 mol %.200. The pharmaceutical composition of claim 194 , wherein the linear sugar alcohol is selected from the group consisting of arabitol claim 194 , erythritol claim 194 , glycerol claim 194 , maltitol claim 194 , mannitol claim 194 , ribitol claim 194 , sorbitol claim 194 , xylitol claim 194 , threitol claim 194 , galactitol claim 194 , isomalt claim 194 , iditol claim 194 , lactitol and combinations thereof.201. The pharmaceutical composition of claim 200 , wherein the linear sugar alcohol is selected from the group consisting of arabitol claim 200 , erythritol claim 200 , glycerol claim 200 , maltitol claim 200 , mannitol claim 200 , ribitol claim 200 , sorbitol claim ...

METHODS FOR PURIFICATION OF A VIRUS PRODUCED IN VITRO AND CLEARANCE ASSAY FOR THE VIRUS

A method of purification of non-enveloped or pseudo-enveloped virus produced in vitro uses a composition with at least one detergent. A method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample includes treating with at least one detergent. 1. A method of purifying a non-enveloped or a pseudo-enveloped virus propagated in cell culture , the method comprising a step of treating a sample comprising the non-enveloped or the pseudo-enveloped virus with a detergent.2. The method according to claim 1 , wherein the virus propagated in cell culture is Hepatitis E Virus (HEV).3. The method according to claim 1 , wherein the virus propagated in cell culture is either Hepatitis A Virus (HAV) or Porcine Parvovirus (PPV).4. The method according to wherein the virus is produced in an in vitro cell culture.5. The method according to claim 4 , wherein the in vitro cell culture comprises an established cell line.6. The method according to claim 5 , wherein the established cell line is selected from a group consisting of HepG2 (ATCC number HB-8065) and HepG2/C3A (ATCC number CRL-10741).7. The method according to claim 1 , wherein the detergent is selected from the group consisting of Lithium Dodecyl Sulfate claim 1 , Triton X-100 and mixtures thereof.8. The method according to claim 7 , wherein a concentration of Triton X-100 is 0.5% and a concentration of Lithium Dodecyl Sulfate is 0.1%.9. The method according to claim 1 , wherein the step of treating is carried out for 1 hour.10. The method according to claim 1 , wherein the sample is a supernatant obtained from ultra-centrifugation of a clarified virus-infected cell lysate suspension.11. The method according to claim 1 , wherein the sample is a retentate derived from transflow filtration of a clarified virus-infected cell lysate suspension.12. A method of measuring a level of a non-enveloped or a pseudo-enveloped virus in a ...

METHOD FOR GENERATING HIGH-TITER HEPATITIS E VIRUS STOCKS AND TITRATION ASSAY FOR HEPATITIS E VIRUS

Polybrene as an additive in cell culture medium is used in methods for the generation of high-titer hepatitis E virus stocks and assays for titration of hepatitis E virus. A cell culture medium containing polybrene is used for high-titer HEV generation, a method for determining the presence and/or the level of HEV in a sample, and an HEV titration assay using polybrene. 1. A method of producing a high titer of Hepatitis E Virus (HEV) , the method comprising:a) culturing a cell line in vitro in a medium comprising a concentration of polybrene, andb) infecting the cell line with HEV.2. The method according to claim 1 , wherein the cell line is HepG2 (ATCC number HB-8065) or HepG2/C3A (ATCC number CRL-10741).3. The method according to claim 1 , wherein the concentration of polybrene is about 1 μg/ml-about 5 μg/ml.4. The method according to claim 1 , wherein the high titer of HEV is about 10copies/mL-about 10copies/mL.5. The method according to claim 1 , wherein the high titer of HEV is about 10copies/mL-about 10copies/mL.6. The method according to claim 1 , wherein the method further comprises the steps of:a) adding a concentration of polybrene to the medium;b) passaging the HEV-infected cell line in the medium comprising polybrene; andc) collecting the medium and/or infected cells.7. The method according to claim 6 , wherein the concentration of polybrene in step b) is about 1 μg/ml-about 5 μg/ml.8. The method according to claim 6 , wherein the high titer of HEV obtained in the medium and/or infected cells is about 10copies/mL-about 10copies/mL.9. The method according to claim 6 , wherein the high titer of HEV obtained in the medium and/or infected cells is about 10copies/mL-about 10copies/mL.10. A method of determining a presence and/or a level of HEV in a sample claim 6 , the method comprising the steps of:a) providing the sample to a mixture comprising a cell line and a culture medium, wherein the culture medium comprises polybrene;b) incubating the mixture ...

Cableless Interconnect

A baseboard includes a first connection configured to electrically interface with a motherboard, a second connection configured to electrically interface with a module, and a switch circuit configured to route data channels and power channels between the motherboard and the module. The first connection is configured to interface with more than one connection protocol or standard. The second connection is configured to interface with the more than one connection protocol or standard. The baseboard allows for cableless connections to allow unobstructed airflow over the components. 1. A baseboard , including:a printed circuit board;a motherboard interface configurable to allow communications between the printed circuit board and a motherboard; anda first ancillary module interface configurable to allow communications between the printed circuit board and a first ancillary module; the motherboard interface is configured to communicate with a plurality of protocols or standards to enable a communication channel between the motherboard and the ancillary module; and', 'the first ancillary module interface is configured to communicate with a plurality of protocols or standards to enable the communication channel between the motherboard and the ancillary module., 'wherein2. The baseboard of claim 1 , further comprising a connector of the printed circuit board connectable to the motherboard and a baseboard connector of the printed circuit board connectable to the first ancillary module claim 1 , wherein the connector and baseboard connector are positioned toward opposite ends of the printed circuit board.3. The baseboard of claim 1 , further comprising a programmable power controller configured to provide a power supply voltage conforming to connection protocols of the motherboard interface or the first ancillary module interface.4. The baseboard of claim 1 , further comprising a second ancillary module interface configurable to allow communications between the printed ...

Interposer For Printed Circuit Boards

A system includes a top printed circuit (PCB) including an array of contact pads, a bottom PCB including an array of contact pads, at least one interposer positioned between the top and bottom PCBs, including: an array of top connectors configured to contact the array of contact pads of the top PCB; an array of bottom connectors configured to contact the array of contact pads of the bottom PCB; and interconnections configured to electrically connect the top connectors and the bottom connectors, at least one spacer element positioned between the top PCB and the bottom PCB and configured to contribute to maintaining a specified distance between the top PCB and the bottom PCB; and at least one fastener of the top PCB and the bottom PCB. The system further includes fasteners configured to press the top PCB, the interposer, the bottom PCB, and the spacer layer together.

Linear polyol stabilized polyfluoroacrylate compositions

The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.

CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA

The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract. 4. The pharmaceutical composition of any one of to wherein the polymer comprises structural units corresponding to Formulae 1 , 2 and 3.5. The pharmaceutical composition of any one of to wherein either:(i) the structural units corresponding to Formula 1 constitute at least about 85 wt. % based on the total weight of structural units of Formulae 1, 2, and 3 in the polymer calculated from the amounts of monomers used in the polymerization reaction, and the weight ratio of the structural unit corresponding to Formula 2 to the structural unit corresponding to Formula 3 is from about 4:1 to about 1:4, or(ii) the mole fraction of the structural unit of Formula 1 in the polymer is at least about 0.87 based on the total number of moles of the structural units of Formulae 1, 2, and 3 calculated from the amounts of monomers used in the polymerization reaction, and the mole ratio of the structural unit of Formula 2 to the structural unit of Formula 3 is from about 0.2:1 to about 7:1.6. The pharmaceutical composition of any one of to wherein the polymer comprises structural units corresponding to Formulae 1 and 2.7. The pharmaceutical composition of any one of to wherein the polymer comprises structural units corresponding to Formulae 1 and 3.10. The pharmaceutical composition of or wherein Ais a protected carboxylic , phosphonic , or phosphoric.12. The pharmaceutical composition of any one of to wherein ...

METHODS AND APPARATUS FOR SCORING THE CONDITION OF NODES IN A COMMUNICATION NETWORK AND TAKING ACTION BASED ON NODE HEALTH SCORES

Methods and apparatus for monitoring a network and generating overall health scores for communications nodes in the network are described. A monitoring system receives information from a variety of system elements and/or devices which provide information relating to communications service. The information received by the network monitoring system includes information indicating the number of outstanding work orders issued in regard to a trouble report, signal power level variance information, signal alarm information, uncorrectable error information, correctable error information, offline device information, etc. A set of scores for a node are generated based on the different types of received information. The scores are combined using a weighted sum to generate an overall node health score. Nodes are ranked based on overall node health scores and maintenance personal can view the scores as well as the underlying information corresponding to a node to facilitate identification of possible faults. 1. A method of monitoring a communications system comprising:receiving information corresponding to a first node relating to a first network portion which includes customer premise devices which communicate via said first node with other devices, said information including at least first offline device information, first communication error information, and first signal level variance information;generating a set of first node condition scores from said received information corresponding to the first node, said step of generating a first set of first node condition scores including generating a first offline device score based on said first offline device information, a first error score based on the first detected error information, and a first signal level variance score based on the first signal level variance information;generating an overall first node health score corresponding to said first node based on a weighted combination of the scores included in said set of ...

LINEAR POLYOL STABILIZED POLYFLUOROACRYLATE COMPOSITIONS

The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract. 3. The process of wherein the polymer comprises structural units corresponding to Formulae 1 claim 1 , 2 and 3.4. The process of wherein the polymer comprises structural units corresponding to Formulae 1 and 2.5. The process of wherein the polymer comprises structural units corresponding to Formulae 1 and 3.6. The process of wherein the cation of the salt is calcium claim 1 , sodium claim 1 , or a combination thereof.7. The process of wherein the cation of the salt comprises calcium.8. The process of wherein the linear sugar alcohol is selected from the group consisting of arabitol claim 1 , erythritol claim 1 , glycerol claim 1 , maltitol claim 1 , mannitol claim 1 , ribitol claim 1 , sorbitol claim 1 , xylitol claim 1 , threitol claim 1 , galactitol claim 1 , isomalt claim 1 , iditol claim 1 , lactitol and combinations thereof.9. The process of wherein the linear sugar alcohol is sorbitol claim 1 , xylitol claim 1 , or a combination thereof.10. The process of wherein the cation of the salt is calcium claim 8 , sodium claim 8 , or a combination thereof.11. The process of wherein the cation of the salt comprises calcium.12. The process of wherein the polymer comprises structural units corresponding to Formulae 1 claim 2 , 2 and 3 claim 2 , the cation of the salt comprises calcium and the linear sugar alcohol comprises sorbitol.14. The process of wherein Ais a protected carboxylic claim 13 , phosphonic claim 13 , or phosphoric.16. The process of wherein the polymer comprises structural units corresponding to Formulae 11 claim 13 , 22 claim 13 , and 33.17. The process of wherein the cation of the salt is calcium claim 13 , sodium claim 13 , or a combination thereof.18. The process of wherein the linear sugar alcohol is selected ...

TREATING HYPERKALEMIA WITH CROSSLINKED CATION EXCHANGE POLYMERS OF IMPROVED PHYSICAL PROPERTIES

The present invention is directed to methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio. 1. A method for removing potassium from the gastrointestinal tract of an animal subject in need thereof comprising administering a potassium binding polymer to the animal subject , the potassium binding polymer being a crosslinked cation exchange polymer comprising acid groups in acid or salt form , the potassium binding polymer being in the form of substantially spherical particles having a mean diameter of from about 20 μm to about 200 μm and less than about 4 volume percent of the particles have a diameter of less than about 10 μm , and the potassium binding polymer having a sediment yield stress of less than about 4000 Pa , and a swelling ratio of less than 10 grams of water per gram of polymer , and wherein the polymer particles in dry form have a compressibility index of less than about 14 , wherein the compressibility index is defined as 100*(TD−BD)/TD , and BD and TD are the bulk density and tap density , respectively.2. (canceled)3. The method of wherein serum potassium level is reduced in the subject.4. The method of wherein the subject is experiencing hyperkalemia.5. The method of wherein the mean diameter is from about 25 μm to about 150 μm.6. The method of wherein the mean diameter is from about 50 μm to about 125 μm.7. The method of any wherein less than about 0.5 volume percent of the particles have a diameter of less than about 10 μm.8. (canceled)9. The method of any wherein less than about 0.5 volume percent of the particles have a diameter of less than about 20 μm.10. (canceled)11. The method of wherein the polymer has a swelling ratio from about 1 to about 5.12. The ...

Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract.

Cross-linked cation exchange polymers, compositions and use in the treatment of hyperkalemia

Methods for purification of a virus produced in vitro and clearance assay for the virus

Provided herein is a method of purification of non-enveloped or pseudo-enveloped virus produced in vitro using a composition with at least one detergent. Also provided are a method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample.

Linear polyol stabilized polyfluoroacrylate compositions

The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.

Methods for purification of a virus produced in vitro and clearance assay for the virus

Provided herein is a method of purification of non-enveloped or pseudo-enveloped virus produced in vitro using a composition with at least one detergent. Also provided are a method of purification using multiple detergents, and a method of determining the, presence and/or concentration of a non-enveloped or pseudo-enveloped virus in a sample.

Methods and apparatus for scoring the condition of nodes in a communication network and taking action based on node health scores

Methods and apparatus for monitoring a network and generating overall health scores for communications nodes in the network are described. A monitoring system receives information from a variety of system elements and/or devices which provide information relating to communications service. The information received by the network monitoring system includes information indicating the number of outstanding work orders issued in regard to a trouble report, signal power level variance information, signal alarm information, uncorrectable error information, correctable error information, offline device information, etc. A set of scores for a node are generated based on the different types of received information. The scores are combined using a weighted sum to generate an overall node health score. Nodes are ranked based on overall node health scores and maintenance personal can view the scores as well as the underlying information corresponding to a node to facilitate identification of possible faults.

PURIFICATION PROCEDURES OF A VIRUS PRODUCED VIRUS AND VIRUS ELIMINATION TEST

En el presente documento se da a conocer un procedimiento para la purificación de un virus no envuelto o pseudoenvuelto producido in vitro que utiliza una composición con al menos un detergente. También se da a conocer un procedimiento para la purificación que puede utilizar múltiples detergentes y un procedimiento para la determinación de la presencia y/o el nivel de un virus no envuelto o pseudoenvuelto en una muestra.

Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus

Provided herein are the use of polybrene as an additive in cell culture medium used in methods for the generation of high-titer hepatitis E virus stocks and assays for titration of hepatitis E virus. Also provided are a cell culture medium containing polybrene for high-titer HEV generation, a method for determining the presence and/or the level of HEV in a sample, and an HEV titration assay using polybrene.

PROCEDURE FOR THE GENERATION OF HIGH SAMPLES HEPATITIS E VIRUS TITLE AND TITULATION TEST FOR HEPATITIS E VIRUS

En el presente documento se da a conocer el uso de polibreno como aditivo en medio de cultivo celular utilizado en procedimientos para la generación de concentrados de virus de la hepatitis E de título alto y ensayos para la titulación del virus de la hepatitis E. También se proporciona un medio de cultivo celular que comprende polibreno para la generación de VHE de título alto, un procedimiento para determinar la presencia y/o el nivel de VHE en una muestra, y un ensayo de titulación del VHE usando polibreno. This document discloses the use of polybrene as an additive in cell culture medium used in procedures for the generation of high-grade hepatitis E virus concentrates and assays for the titration of the hepatitis E virus. provides a cell culture medium comprising polybrene for the generation of high titer HEV, a procedure for determining the presence and / or level of HEV in a sample, and a HEV titration assay using polybrene.

Methods for purification of a virus produced in vitro and clearance assay for the virus

Methods for purification of a virus produced in vitro and clearance assay for the virus

Methods for purification of a virus produced in vitro and clearance assay for the virus Provided herein is a method of purification of non-enveloped or pseudo-enveloped virus produced in vitro using a composition with at least one detergent. Also provided are a method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample.

Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract.

Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus

CROSS-EXTENDED CATION EXCHANGE POLYMERS, COMPOSITIONS AND APPLICATIONS FOR TREATMENT OF HYPERCALIA

Procedures for purification of a virus produced in vitro and virus elimination assay

Procedimiento de purificación de un virus no envuelto o pseudoenvuelto propagado en un cultivo celular, comprendiendo el procedimiento una etapa de tratar una muestra que comprende el virus no envuelto o pseudoenvuelto con un detergente, caracterizado por que el detergente se selecciona del grupo que consiste en Tritón X-100 al 0,5% y una mezcla de Tritón X-100 al 0,5% y dodecil sulfato de litio al 0,1%. Method of purification of a non-enveloped or pseudo-enveloped virus propagated in a cell culture, the method comprising a step of treating a sample comprising the non-enveloped or pseudo-enveloped virus with a detergent, characterized in that the detergent is selected from the group consisting of Triton 0.5% X-100 and a mixture of 0.5% Triton X-100 and 0.1% lithium dodecyl sulfate.

Methods for purification of a virus produced in vitro and clearance assay for the virus

A method of purification of non-enveloped or pseudo-enveloped virus produced in vitro uses a composition with at least one detergent. A method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample includes treating with at least one detergent.

Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such polymer. Crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio are also described. These polymers and compositions are useful to bind potassium in the gastrointestinal tract.

Methods for purification of a virus produced in vitro and clearance assay for the virus

Provided herein is a method of purification of non-enveloped or pseudo-enveloped virus produced in vitro using a composition with at least one detergent. Also provided are a method of purification using multiple detergents, and a method of determining the, presence and/or concentration of a non-enveloped or pseudo-enveloped virus in a sample.